The results were posted Tuesday. For the same quarter last year, AtriCure had a net loss of $764,506, according to the company.
A year after the company launched its AtriClip system product, it said it plans the commercial release in the U.S. of two products this quarter: Isolator Synergy Access clamp, which allow surgeons to more easily place the clamp into position during open-heart ablation procedures; and cryoICE BOX, a cardiac cryosurgical ablation system.
Surgical ablation, the scarring of tissue, is a method to treat abnormal heart rhythms.
Despite a larger net loss than a year ago, AtriCure said it had record total revenues before expenses of $16.8 million, an increase of 18.2 percent from the same quarter last year. But operating expenses increased 11.9 percent for increases in clinical and regulatory related costs and activities and increases in selling personnel, according to AtriCure.
AtriCure was started in 2000 and went public in 2005. According to the company, it makes products for use in cardiac surgical ablation.